Inflammatory bone loss is caused by a complex pathway that begins with inflammatory cell production of cytokines, progresses to abnormal bone absorption, and culminates in the destruction of joints, bone fractures, and patient debility.
Inflammatory bone loss is caused by a complex pathway that begins with inflammatory cell production of cytokines, progresses to abnormal bone absorption, and culminates in the destruction of joints, bone fractures, and patient debility.
George Schett, MD, professor of internal medicine and rheumatology from Universitatsklinikum Erlanger, discussed the pathophysiology of bone loss at the 2014 American Society of Bone and Mineral Research Conference in Houston, Texas.
He began by noting that inflammation plays a significant role in body and bone homeostasis. A slight elevation of C-reactive protein (CRP), suggesting a small amount of inflammation, can increase a patient’s fracture risk. Therefore, patients with diseases that result in continuous inflammation have a much higher risk of fractures and loss of bone mass. Examples of these vulnerable patients include not only those with rheumatoid arthritis, osteoarthritis, and juvenile arthritis, but also patients with localized inflammation in one organ system like Crohn’s disease (gut inflammation) and patients with psoriasis (skin inflammation).
Dr Schett described patients suffering from chronic inflammatory diseases as “swimming in a sea of cytokines.” The path of inflammation-induced bone loss in rheumatoid arthritis begins when inflammatory cells produce large amounts of cytokines. Among other functions, cytokines encourage the activity of osteoclasts, resulting in increased bone absorption. As the osteoclasts accumulate, they dig tunnels underneath the cartilage, destroy joint architecture and debilitate patients.
Systemic inflammation associated with rheumatoid arthritis destroys cortical and trabecular bone structure. In order to stop the decline in bone mass, patients must be treated with anti-inflammatory medications to decrease cytokine levels. Cytokines decrease bone mass in a number of ways. Some, like TNF-alpha and IL-6, inhibit bone formation and suppress intrinsic repair mechanisms. Others, like B cells, interfere with the function of other cells
Therefore, cytokine blockers (such as TNF or IL-6 blockers) can end bone loss and also induce the repair of previous bone damage. Dr Schett noted that the development of targeted cytokine antibodies may lead to new modalities for bone repair in the future.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More